Celcuity Inc's stock rose by 5.19% as it crossed above the 5-day SMA, despite the broader market decline with the Nasdaq-100 down 1.79% and the S&P 500 down 1.08%.
This increase is attributed to the company's recent updates on gedatolisib clinical data, revealing a median progression-free survival (PFS) of 16.6 months in the VIKTORIA-1 trial, significantly outperforming the 1.9 months seen with fulvestrant alone. The positive results highlight the therapy's potential for HR+, HER2- breast cancer patients, suggesting a transformative impact on treatment options.
The implications of this data are substantial, as it not only supports future FDA New Drug Application submissions but also positions Celcuity favorably in the oncology market, potentially attracting more investor interest and enhancing its market valuation.
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 106.50 USD with a low forecast of 94.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 106.50 USD with a low forecast of 94.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 114.530
Low
94.00
Averages
106.50
High
126.00
Current: 114.530
Low
94.00
Averages
106.50
High
126.00
Wells Fargo
initiated
$126
2025-12-12
Reason
Wells Fargo
Price Target
$126
AI Analysis
2025-12-12
initiated
Reason
As previously reported, Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target. The firm believes the upcoming VIKTORIA-1 PI3KCA mutant readout is largely de-risked by the wild-type readout and Phase 1. The current stock price doesn't reflect gedatolisib's market opportunity in breast cancer and metastatic castration-resistant prostate cancer is a free call option at these levels, Wells adds.
Wells Fargo
initiated
$126
2025-12-12
Reason
Wells Fargo
Price Target
$126
2025-12-12
initiated
Reason
Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CELC
Unlock Now
Wolfe Research
Outperform
initiated
$110
2025-11-17
Reason
Wolfe Research
Price Target
$110
2025-11-17
initiated
Outperform
Reason
Wolfe Research initiated coverage of Celcuity with an Outperform rating and $110 price target. Fresh off a Phase 3 win for gedatolisib in second-line PIK3CA-wt breast cancer, the firm sees additional upside as the PIK3CA-mt readout looks "primed to deliver next year," the analyst tells investors. The firm views Celcuity as "a top-tier acquisition opportunity for big pharma," the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$77 -> $94
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$77 -> $94
2025-11-17
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Celcuity to Neutral from Buy with a price target of $94, up from $77. The shares look "priced for perfection," the analyst tells investors in a research note. The firm says Celcuity shares have appreciated 608% year-to-date. At current levels, there is more downside risk than upside, contends H.C. Wainwright.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
